Related Experiment Video

Updated: Sep 30, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

[Hemodynamic and metabolic disturbances in patients with hypertension with and without obesity]

V H Lizohub, Zh A Hryshkova

    Likars'Ka Sprava
    |July 31, 2002
    PubMed

    Insights

    Patients with hypertension and obesity show worse lipid profiles and increased heart strain. Obesity exacerbates hypertensive disease, leading to higher blood pressure and cardiac changes.

    Area of Science:

    • Cardiology
    • Metabolic Diseases
    • Hypertension Research

    Context:

    • Hypertensive disease (HD) and obesity are common comorbidities.
    • Understanding their combined impact on cardiovascular health is crucial.

    Purpose:

    • To investigate the effects of concomitant hypertensive disease and obesity on central hemodynamics and lipid profiles.
    • To compare cardiovascular parameters between patients with and without obesity.

    Summary:

    • Patients with both HD and obesity exhibited more proatherogenic lipid changes, left ventricular hypertrophy, and cardiac chamber dilatation.
    • These patients also showed elevated 24-hour systolic, diastolic, and mean arterial pressure (AP) levels, along with increased hypertension time indices.
    • The non-dipper pattern was predominant in the 24-hour AP profiles of patients with HD and obesity.

    Impact:

    • Obesity significantly worsens cardiovascular risk in hypertensive patients.
    • Findings highlight the need for integrated management of hypertension and obesity.
    • This research contributes to understanding the pathophysiology of combined cardiovascular risk factors.

    More Related Videos

    Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome06:04

    Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

    Published on: September 27, 2024

    Related Concept Videos

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    Hypertension and Regulation of Blood Pressure01:18

    Hypertension and Regulation of Blood Pressure

    Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
    Drug Dosing: Obese Patients01:21

    Drug Dosing: Obese Patients

    In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

    Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

    Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
    Alterations in Blood Pressure01:30

    Alterations in Blood Pressure

    Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
    Hypertension (High blood pressure)
    Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart beats)...